Clinical studies of the effect of a Dengzhan Shengmai capsules onnon-arteritic ischemic optic neuropathy
ZHU Chengyi,YI Qiong,MA Jinli,WEI Qiping
Department of Ophthalmology, Beijing He Ping Li Hospital, Beijing 100013, China; 2. Department of Ophthalmology, Dongfang Hospital of Beijing University of Chinese Medicine, Beijing 100078, China.
Objective To evaluate the clinical efficacy of Dengzhan Shengmai capsules for patients with non-arteritic anterior ischemic optic neuropathy (NAION). Methods A total of 120 patients with NAION were enrolled in a randomized controlled trial. Of those, 60 control patients were treated only with compound anisodine (CA, 2 ml/injection, 1 per day) (the control group), while the remaining 60 patients, designated, the combination group, received a combined treatment of CA and a Dengzhan Shengmai capsule, 0.36 g/dose, 3 times/day (the combination group). Patients were followed for 3 months, and the overall curative effect, visual acuity, visual field mean sensitivity, and hemorheology indicators were measured. Data were analyzed using the Wilcoxon test and the t test. Results Forty-nine patients (70 eyes) in the control group and 51 patients (72 eyes) in the combination treatment group were followed for 3 months or more. Compared to the control group, the combination treatment produced significantly higher visual acuity and visual field mean sensitivity (t=-5.223, -3.690, P＜0.05). In the combination group the plasma viscosity, whole blood high shear viscosity, low shear viscosity, hematokrit, and plasma fibrin were significantly lower than in the control group (t=1.224, 3.114, 7.458, 9.153, 2.105, respectively, P＜0.05 for each). The total effective rates were 88% and 71% for the combination group and control group, respectively (Z=2.890, P＜0.01). Conclusion Our results show that a combination of CA and Dengzhan Shengmai capsules improves visual acuity, visual field mean sensitivity and hemorheology indicators for NAION patients.
Verma R, Gupta M, Chaudhari TS. Neurogenic vision loss: Causes and outcome. An experience from a tertiary center in Northern India[J]. J Neurosci Rural Pract,2014,5(4):340-348. DOI:10.4103/0976-3147.139971.
[2]
Hayreh SS. Ischemic optic neuropathies-where are we now?[J]. Graefes Arch Clin Exp Ophthalmol,2013,251(8):1873-1884. DOI:10.1007/s00417-013-2399-z.
[3]
Chua D, Cullen JF. Incipient non-arteritic anterior ischaemic optic neuropathy: a distinct clinical entity, the Singapore scene 3[J]. Singapore Med J,2014,55(9):473-475.
[4]
Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome[J]. Prog Retin Eye Res,2014,41:1-25. DOI: 10.1016/j.preteyeres.2014.04.001.
Reddy D, Rani PK, Jalali S, et al. A study of prevalence and risk factors of diabetic retinopathy in patients with non-arteritic anterior ischemic optic neuropathy (NA-AION)[J]. Semin Ophthalmol,2015,30(2):101-104. DOI:10.3109/08820538.2013.8332-62.
Sung J, Sung M, Kim Y, et al. Anti-inflammatory effect of methanol extract from Erigeron Canadensis L. may be involved with upregulation of heme oxygenase-1 expression and suppression of NFκB and MAPKs activation in macrophages[J]. Nutr Res Pract,2014,8(4):352-359. DOI:10.4162/nrp.2014.8.4.352.
[11]
Li J, Yu DQ. Two new constituents from Erigeron breviscapus[J]. J Asian Nat Prod Res,2013,15(9):969-973. DOI:10.1080/ 10286020.2013.826206.
[12]
Sukrittanon S, Watanapa WB, Ruamyod K. Ginsenoside Reenhances small-conductance Ca(2+)-activated K(+) current in human coronary artery endothelial cells[J]. Life Sci,2014,115(1-2):15-21. DOI:10.1016/j.lfs.2014.09.007.
[13]
S?覬rensen AD, Durand E, Laguerre M, et al. Antioxidant properties and efficacies of synthesized alkyl caffeates, ferulates, and coumarates[J]. J Agric Food Chem,2014,62(52):12553-12562. DOI:10.1021/jf500588s.
[14]
Shang YH, Tian JF, Hou M, et al. Progress on the protective effect of compounds from natural medicines on cerebral ischemia[J]. Chin J Nat Med,2013,11(6):588-595. DOI:10.1016/ S1875-5364(13)60068-0.
[15]
Guo C, Zhu Y, Weng Y, et al. Therapeutic time window and underlying therapeutic mechanism of breviscapine injection against cerebral ischemia/reperfusion injury in rats[J]. J Ethnopharmacol,2014,151(1):660-666. DOI:10.1016/j.jep.2013.11.026.
[16]
Yang XD, Yang YY, Ouyang DS, et al. A review of biotransformation and pharmacology of ginsenoside compound K[J]. Fitoterapia,2015,100:208-220. DOI:10.1016/j.fitote.2014.11.019.
浙公网安备 33030202001892号